Cargando…

Co-occurring genomic alterations and immunotherapy efficacy in NSCLC

An oncogene-centric molecular classification paradigm in non-small cell lung cancer (NSCLC) has been established. Of note, the heterogeneity within each oncogenic driver-defined subgroup may be captured by co-occurring mutations, which potentially impact response/resistance to immune checkpoint inhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Fan, Wang, Jinliang, Xu, Yu, Cai, Shangli, Li, Tao, Wang, Guoqiang, Li, Chengcheng, Zhao, Lei, Hu, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766442/ https://www.ncbi.nlm.nih.gov/pubmed/35042953 http://dx.doi.org/10.1038/s41698-021-00243-7

Ejemplares similares

Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC
por: Zhang, Zhimin, et al.
Publicado: (2021)

Complement and coagulation cascades pathway-related signature as a predictor of immunotherapy in metastatic urothelial cancer
por: Gong, Zheng, et al.
Publicado: (2023)

Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy
por: Zhang, Fan, et al.
Publicado: (2020)

Bifidobacterium breve predicts the efficacy of anti‐PD‐1 immunotherapy combined with chemotherapy in Chinese NSCLC patients
por: Zhao, Honghui, et al.
Publicado: (2022)

Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer
por: Han, Sujun, et al.
Publicado: (2023)

Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
por: Xing, Puyuan, et al.
Publicado: (2019)

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC
por: Sun, Yiting, et al.
Publicado: (2021)

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC
por: Wang, Zemin, et al.
Publicado: (2022)

The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC
por: Wang, Shuhang, et al.
Publicado: (2020)

Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients
por: Yang, Wenchao, et al.
Publicado: (2022)

Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade
por: Wang, Shuhang, et al.
Publicado: (2022)

Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC
por: He, Yayi, et al.
Publicado: (2021)

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes
por: Mazzotta, Marco, et al.
Publicado: (2020)

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
por: Yang, Yudie, et al.
Publicado: (2022)

Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer
por: Zhang, Fan, et al.
Publicado: (2020)

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
por: Yuan, Bo, et al.
Publicado: (2020)

Driver gene alterations profiling of Chinese non‐small cell lung cancer and the effects of co‐occurring alterations on immunotherapy
por: Sun, Shengjie, et al.
Publicado: (2021)

Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients
por: Song, Peng, et al.
Publicado: (2020)

Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC
por: Rogado, Jacobo, et al.
Publicado: (2022)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC
por: Wang, Yuntao, et al.
Publicado: (2022)

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma
por: Bai, Hua, et al.
Publicado: (2020)

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers
por: Adashek, Jacob J., et al.
Publicado: (2021)

The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis
por: Zhou, Liang, et al.
Publicado: (2016)

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Li, Teng, et al.
Publicado: (2021)

Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
por: Lv, Lulu, et al.
Publicado: (2022)

Circulating cell-free DNA for cancer early detection
por: Gao, Qiang, et al.
Publicado: (2022)

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
por: Li, Ye, et al.
Publicado: (2020)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Immunotherapy and NSCLC: The Long and Winding Road
por: Rossi, Antonio
Publicado: (2020)

Immunotherapy in NSCLC Patients with Brain Metastases
por: Buriolla, Silvia, et al.
Publicado: (2022)

Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy
por: Zarogoulidis, Paul, et al.
Publicado: (2022)

Erratum: The landscape of immunotherapy resistance in NSCLC
Publicado: (2023)

Naturally Occurring Genetic Alterations in Proximal TCR Signaling and Implications for Cancer Immunotherapy
por: Kent, Andrew, et al.
Publicado: (2021)

Lung microbiome alterations in NSCLC patients
por: Zheng, Leliang, et al.
Publicado: (2021)

Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC
por: Hu, Rong, et al.
Publicado: (2020)

GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC
por: Fan, Honghong, et al.
Publicado: (2023)

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms
por: Liu, Zhichao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sv3k6b7r64u93dkrldcn9do1l9